Research graph
References from Impact of busulfan exposure stratification on transplant outcomes and immune reconstitution in children with severe aplastic anemia. Local targets link to admitted publications; unresolved targets remain external evidence.
Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis
10.1016/s2352-3026(16)30114-4 · 2016 · External reference
Immune reconstitution in pediatric patients following hematopoietic cell transplant for non-malignant disorders
10.3389/fimmu.2020.01988 · 2020 · External reference
Busulfan target exposure attainment in children undergoing allogeneic hematopoietic cell transplantation: a single day versus a multiday therapeutic drug monitoring regimen
10.1038/s41409-023-01971-z · 2023 · External reference
Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity
10.1182/bloodadvances.2024013275 · 2024 · External reference
Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation
10.1046/j.1365-2125.2002.01555.x · 2002 · External reference
A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT)
10.1038/s41409-024-02413-0 · 2024 · External reference
Busulfan systemic exposure and its relationship with efficacy and safety in hematopoietic stem cell transplantation in children: a meta-analysis
10.1186/s12887-020-02028-6 · 2020 · External reference
Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP)
10.1016/j.bcmd.2024.102860 · 2024 · External reference
Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study
10.1016/s0140-6736(13)62069-3 · 2014 · External reference
Role of therapeutic drug monitoring of intravenous busulfan for prevention of sinusoidal obstructive syndrome in children
10.1111/petr.14266 · 2022 · External reference
International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai acute GVHD international consortium
10.1016/j.bbmt.2015.09.001 · 2016 · External reference
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report
10.1016/j.bbmt.2014.12.001 · 2015 · External reference
A limited sampling strategy for estimating busulfan exposure in pediatric hematopoietic stem cell transplantation
10.3389/fphar.2025.1540139 · 2025 · External reference
Intra-individual pharmacokinetic variability of intravenous busulfan in hematopoietic stem cell-transplanted children
10.1007/s40262-020-00877-z · 2020 · External reference
Use of multivariate immune reconstitution patterns to describe immune reconstitution after allogeneic stem cell transplantation in children
10.1016/j.bbmt.2019.06.018 · 2019 · External reference
Incidence, management, and prognosis of graft failure and autologous reconstitution after allogeneic hematopoietic stem cell transplantation
10.3346/jkms.2021.36.e151 · 2021 · External reference
Unresolved reference
2023 · External reference
1994 Consensus conference on Acute GVHD grading
1995 · External reference
Model-informed precision dosing of intravenous busulfan in Thai pediatrics undergoing hematopoietic stem cell transplantation
10.1097/ftd.0000000000001225 · 2024 · External reference
Unresolved reference
2022 · External reference
Reduced intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases
10.1038/sj.bmt.1705923 · 2008 · External reference
Population pharmacokinetic modeling for twice-daily intravenous busulfan in a large cohort of pediatric patients undergoing hematopoietic stem cell transplantation—a 10-year single-center experience
10.3390/pharmaceutics16010013 · 2023 · External reference
Clinical outcomes of individualized busulfan-dosing in hematopoietic stem cell transplantation in Chinese children undergoing with therapeutic drug monitoring
10.1038/s41409-021-01545-x · 2022 · External reference
Treatment of relapsed/refractory severe aplastic anemia in children: evidence-based recommendations
10.1002/pbc.31075 · 2024 · External reference
Immune reconstitution in pediatric aplastic anemia after allogeneic hematopoietic stem-cell transplantation
10.7150/ijms.70146 · 2022 · External reference
Acquired aplastic anemia therapies: immunosuppressive therapy versus alternative donor hematopoietic cell transplantation
10.14740/jh1264 · 2024 · External reference
Immunoglobulin levels of children with bronchiolitis obliterans syndrome after hematopoietic cell transplantation
10.3389/fmed.2025.1692881 · 2026 · External reference
